litlas
Log inCreate account

Clare L. Scott

Active 1997–2025

100
Papers
23,969
Citations
63
h-index
94
i10-index

Citations

Citations per year for Clare L. Scott1991: 1 citations1992: 1 citations1997: 3 citations1998: 6 citations2000: 20 citations2001: 28 citations2002: 38 citations2003: 35 citations2004: 37 citations2005: 34 citations2006: 27 citations2007: 60 citations2008: 89 citations2009: 71 citations2010: 126 citations2011: 193 citations2012: 194 citations2013: 195 citations2014: 203 citations2015: 233 citations2016: 292 citations2017: 320 citations2018: 371 citations2019: 1,094 citations2020: 1,302 citations2021: 1,149 citations2022: 938 citations2023: 679 citations2024: 1,003 citations2025: 379 citations2026: 12 citations1993–1996: no citations, so these years are not shown1999: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,498 citing papers, 24.5% of this breakdownChina: 949 citing papers, 9.3% of this breakdownUnited Kingdom: 877 citing papers, 8.6% of this breakdownAustralia: 706 citing papers, 6.9% of this breakdownItaly: 557 citing papers, 5.5% of this breakdownGermany: 456 citing papers, 4.5% of this breakdownCanada: 438 citing papers, 4.3% of this breakdownFrance: 419 citing papers, 4.1% of this breakdownSpain: 319 citing papers, 3.1% of this breakdownJapan: 319 citing papers, 3.1% of this breakdownNetherlands: 238 citing papers, 2.3% of this breakdownSouth Korea: 169 citing papers, 1.7% of this breakdown
0%24.5%Other 22.1%

Institutions

Fields

  • Medicine58.3%
  • Biochemistry, Genetics and Molecular Biology33.9%
  • Immunology and Microbiology3.1%
  • Neuroscience1.4%
  • Psychology0.7%
  • Computer Science0.6%
  • Other2%

Topics

  • PARP inhibition in cancer therapy11.2%
  • Ovarian cancer diagnosis and treatment6.8%
  • DNA Repair Mechanisms5.5%
  • BRCA gene mutations in cancer3.8%
  • Cell death mechanisms and regulation2.9%
  • Cancer Genomics and Diagnostics2.6%
  • Other67.2%

Coauthors

All papers

Open in search
  1. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

    Authors: Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle, Val Gebski, Richard T. Penson, Amit M. Oza, Jacob Korach, Tomasz Huzarski, Andrés Poveda, Sandro Pignata, Michael Friedländer, Nicoletta Colombo, Philipp Harter, Keiichi Fujiwara, Isabelle Ray‐Coquard, Susana Banerjee, Joyce F. Liu, Elizabeth Lowe, Ralph Bloomfield, Patricia Pautier, Jacob Korach, Tomasz Huzarski, Tomasz Byrski, Patricia Pautier, Michael Friedländer, Philipp Harter, Nicoletta Colombo, Sandro Pignata, Giovanni Scambia, Maria Ornella Nicoletto, Fiona Nussey, Andrew R. Clamp, Richard T. Penson, Amit M. Oza, A. Poveda Velasco, Manuel Rodrigues, Jean‐Pierre Lotz, Frédèric Selle, Isabelle Ray‐Coquard, Diane Provencher, Aleix Prat Aparicio, Laura Vidal Boixader, Clare L. Scott, Kenji Tamura, Mayu Yunokawa, Alla Lisyanskaya, Jacques Médioni, Nicolas Pécuchet, Coraline Dubot, Thibault De La Motte Rouge, Marie‐Christine Kaminsky, B. Weber, Alain Lortholary, Christine Parkinson, Jonathan A. Ledermann, Sarah Williams, Susana Banerjee, Jonathan A. Cosin, James Hoffman, Richard T. Penson, Marie Plante, Allan Covens, Gabe S. Sonke, Florence Joly, Anne Floquet, Susana Banerjee, Holger W. Hirte, Amnon Amit, Tjoung-Won Park-Simon, Koji Matsumoto, Sergei Tjulandin, Jae‐Hoon Kim, Laurence Gladieff, Roberto Sabbatini, David M. O’Malley, Patrick Timmins, Daniel Kredentser, Nuria Laínez Milagro, M.P. Barretina Ginesta, Ariadna Tibau Martorell, Alfonso Gómez de Liaño, Belén Ojeda González, Linda Mileshkin, Masaki Mandai, Ingrid Boere, Petronella B. Ottevanger, Joo‐Hyun Nam, Elias Abdo Filho, Salima Hamizi, Francesco Cognetti, David Warshal, Elizabeth Dickson-Michelson, Scott Kamelle, Nathalie D. McKenzie, Gustavo C. Rodriguez, Deborah K. Armstrong, Eva Chalas, Paul Celano, Kian Behbakht, Susan A. Davidson and 21 more - The Lancet Oncology 2017 cited by 1,863

  2. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: Robert L. Coleman, Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I. Weberpals, Andrew R. Clamp, Giovanni Scambia, Alexandra Léary, Robert W. Holloway, Margarita Amenedo, Peter C.C. Fong, Jeffrey C. Goh, David M. O’Malley, Deborah K. Armstrong, Jesús García-Donás, Elizabeth M. Swisher, Anne Floquet, Gottfried E. Konecny, Iain A. McNeish, Clare L. Scott, T. Cameron, Lara Maloney, Jeff Isaacson, Sandra Goble, Caroline A. Grace, Thomas C. Harding, Mitch Raponi, James Sun, Kevin Lin, Heidi Giordano, Jonathan A. Ledermann, Martin Buck, Andrew Dean, Michael Friedländer, Jeffrey C. Goh, Paul R. Harnett, Ganessan Kichenadasse, Clare L. Scott, Hannelore Denys, Luc Dirix, Ignace Vergote, Laurie Elit, Prafull Ghatage, Amit M. Oza, Marie Plante, Diane Provencher, Johanne I. Weberpals, Stephen Welch, Anne Floquet, Laurence Gladieff, Florence Joly, Alexandra Léary, Alain Lortholary, Jean‐Pierre Lotz, Jacques Médioni, Olivier Trédan, Benoît You, Ayşe Balat, Claudia Hänle, Petra Krabisch, Tanja Neunhöffer, Martin Pölcher, Pauline Wimberger, A Amit, Svetlana Kovel, Michelle Leviov, Tamar Safra, Ronnie Shapira‐Frommer, Salomon M. Stemmer, Alessandra Bologna, Nicoletta Colombo, Domenica Lorusso, Sandro Pignata, Roberto Sabbatini, Giovanni Scambia, Stefano Tamberi, Claudio Zamagni, Peter C.C. Fong, Anne O’Donnell, Margarita Amenedo, A. Casado Herráez, Jesús García-Donás, E.M. Guerra, Ana Oaknin, Isabel Palacio, Ignacio Romero, A Sanchez, Susana Banerjee, Andrew R. Clamp, Yvette Drew, Hani Gabra, D Jackson, JA Ledermann, Iain A. McNeish, C. A. Parkinson, Melanie Powell, Carol Aghajanian and 17 more - The Lancet 2017 cited by 1,704

  3. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

    Authors: David D.L. Bowtell, Steffen Böhm, Ahmed A. Ahmed, Paul‐Joseph Aspuria, Robert C. Bast, Valerie Beral, Jonathan S. Berek, Michael J. Birrer, Sarah P. Blagden, Michael A. Bookman, James D. Brenton, Katherine B. Chiappinelli, Filipe Correia Martins, George Coukos, Ronny Drapkin, Richard J. Edmondson, Christina Fotopoulou, Hani Gabra, Jérôme Galon, Charlie Gourley, Valerie Heong, David G. Huntsman, Marcin Iwanicki, Beth Y. Karlan, Allyson Kaye, Ernst Lengyel, Douglas A. Levine, Karen H. Lu, Iain A. McNeish, Usha Menon, Steven A. Narod, Brad H. Nelson, Kenneth P. Nephew, Paul D.P. Pharoah, Daniel J. Powell, Pilar Ramos, Iris L. Romero, Clare L. Scott, Anil K. Sood, Euan A. Stronach, Frances R. Balkwill - Nature reviews. Cancer 2015 cited by 1,425

  4. Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

    Authors: Jonathan A. Ledermann, Philipp Harter, Charlie Gourley, Michael Friedländer, Ignace Vergote, Gordon Rustin, Clare L. Scott, Werner Meier, Ronnie Shapira‐Frommer, Tamar Safra, Daniela Matei, Euan Macpherson, Claire Watkins, James Carmichael, Ursula A. Matulonis - New England Journal of Medicine 2012 cited by 1,891

  5. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

    Authors: Elizabeth M. Swisher, Kevin Lin, Amit M. Oza, Clare L. Scott, Heidi Giordano, James Sun, Gottfried E. Konecny, Robert L. Coleman, Anna V. Tinker, David M. O’Malley, Rebecca Kristeleit, Ling Ma, Katherine M. Bell‐McGuinn, James D. Brenton, Janiel M. Cragun, Ana Oaknin, Isabelle Ray‐Coquard, Maria I. Harrell, Elaina Mann, Scott H. Kaufmann, Anne Floquet, Alexandra Léary, Thomas C. Harding, Sandra Goble, Lara Maloney, Jeff Isaacson, Andrew R. Allen, Lindsey Rolfe, Roman Yelensky, Mitch Raponi, Iain A. McNeish - The Lancet Oncology 2016 cited by 1,200

  6. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

    Authors: Andrés Poveda, Anne Floquet, Jonathan A. Ledermann, Rebecca Asher, Richard T. Penson, Amit M. Oza, Jacob Korach, Tomasz Huzarski, Sandro Pignata, Michael Friedländer, Alessandra Baldoni, Tjoung-Won Park-Simon, Kenji Tamura, Gabe S. Sonke, Alla Lisyanskaya, Jae‐Hoon Kim, Elias Abdo Filho, Tsveta Milenkova, Elizabeth Lowe, Philip Rowe, Ignace Vergote, Éric Pujade-Lauraine, Jacob Korach, Tomasz Huzarski, Tomasz Byrski, Patricia Pautier, Michael Friedländer, Philipp Harter, Nicoletta Colombo, Sandro Pignata, Giovanni Scambia, Maria Ornella Nicoletto, Fiona Nussey, Andrew R. Clamp, Richard T. Penson, Amit M. Oza, A. Poveda Velasco, Manuel Rodrigues, Jean‐Pierre Lotz, Frédèric Selle, Isabelle Ray‐Coquard, Diane Provencher, Aleix Prat Aparicio, Laura Vidal Boixader, Clare L. Scott, Kenji Tamura, Mayu Yunokawa, Alla Lisyanskaya, Jacques Médioni, Nicolas Pécuchet, Coraline Dubot, Thibault De La Motte Rouge, Marie‐Christine Kaminsky, B. Weber, Alain Lortholary, Christine Parkinson, Jonathan A. Ledermann, Sarah Williams, Susana Banerjee, Jonathan A. Cosin, James Hoffman, Richard T. Penson, Marie Plante, Allan Covens, Gabe S. Sonke, Florence Joly, Anne Floquet, Susana Banerjee, Holger W. Hirte, Amnon Amit, Tjoung-Won Park-Simon, Koji Matsumoto, Sergei Tjulandin, Jae‐Hoon Kim, Laurence Gladieff, Roberto Sabbatini, David M. O’Malley, Patrick Timmins, Daniel Kredentser, Nuria Laínez Milagro, M.P. Barretina Ginesta, Ariadna Tibau Martorell, Alfonso Gómez de Liaño, Belén Ojeda González, Linda Mileshkin, Masaki Mandai, Ingrid Boere, Petronella B. Ottevanger, Joo‐Hyun Nam, Elias Abdo Filho, Salima Hamizi, Francesco Cognetti, David Warshal, Elizabeth Dickson-Michelson, Scott Kamelle, Nathalie D. McKenzie, Gustavo C. Rodriguez, Deborah K. Armstrong, Eva Chalas, Paul Celano and 23 more - The Lancet Oncology 2021 cited by 416

  7. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer

    Authors: Rowan Miller, Alexandra Léary, Clare L. Scott, Violeta Serra, Christopher J. Lord, David D.L. Bowtell, David K. Chang, Dale W. Garsed, Jos Jonkers, Jonathan A. Ledermann, Serena Nik‐Zainal, Isabelle Ray‐Coquard, Sohrab P. Shah, Xavier Matías‐Guiu, Elizabeth M. Swisher, Lucy Yates - Annals of Oncology 2020 cited by 481

  8. BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

    Authors: Kevin Lin, Maria I. Harrell, Amit M. Oza, Ana Oaknin, Isabelle Ray‐Coquard, Anna V. Tinker, Elena Helman, Marc R. Radke, Carmen Say, Lan-Thanh Vo, Elaina Mann, Jeffrey D. Isaacson, Lara Maloney, David M. O’Malley, Setsuko K. Chambers, Scott H. Kaufmann, Clare L. Scott, Gottfried E. Konecny, Robert L. Coleman, James Sun, Heidi Giordano, James D. Brenton, Thomas C. Harding, Iain A. McNeish, Elizabeth M. Swisher - Cancer Discovery 2018 cited by 432

  9. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

    Authors: Jonathan A. Ledermann, Philipp Harter, Charlie Gourley, Michael Friedländer, Ignace Vergote, Gordon Rustin, Clare L. Scott, Werner Meier, Ronnie Shapira‐Frommer, Tamar Safra, Daniela Matei, Anitra Fielding, Stuart Spencer, Brian Dougherty, Maria Orr, Darren Hodgson, J. Carl Barrett, Ursula A. Matulonis - The Lancet Oncology 2014 cited by 1,443

  10. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

    Authors: M. William Audeh, James Carmichael, Richard T. Penson, Michael Friedländer, Bethan Powell, Katherine M. Bell‐McGuinn, Clare L. Scott, Jeffrey N. Weitzel, Ana Oaknin, Niklas Loman, Karen H. Lu, Rita K. Schmutzler, Ursula A. Matulonis, Mark Wickens, Andrew Tutt - The Lancet 2010 cited by 2,283

  11. Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

    Authors: Olga Kondrashova, Minh Nguyen, Kristy Shield‐Artin, Anna V. Tinker, Nelson N.H. Teng, Maria I. Harrell, Michael J. Kuiper, Gwo‐Yaw Ho, Holly E. Barker, Maria Jasin, Rohit Prakash, Elizabeth M. Kass, Meghan R. Sullivan, Gregory J. Brunette, Kara A. Bernstein, Robert L. Coleman, Anne Floquet, Michael Friedländer, Ganessan Kichenadasse, David M. O’Malley, Amit M. Oza, James Sun, Liliane Robillard, Lara Maloney, David D.L. Bowtell, Heidi Giordano, Matthew J. Wakefield, Scott H. Kaufmann, Andrew D. Simmons, Thomas C. Harding, Mitch Raponi, Iain A. McNeish, Elizabeth M. Swisher, Kevin Lin, Clare L. Scott - Cancer Discovery 2017 cited by 417

  12. Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)

    Authors: Elizabeth M. Swisher, Tanya T. Kwan, Amit M. Oza, Anna V. Tinker, Isabelle Ray‐Coquard, Ana Oaknin, Robert L. Coleman, Carol Aghajanian, Gottfried E. Konecny, David M. O’Malley, Alexandra Léary, Diane Provencher, Stephen Welch, Lee-may Chen, Andrea E. Wahner Hendrickson, Ling Ma, Prafull Ghatage, Rebecca Kristeleit, Oliver Dorigo, Ashan Musafer, Scott H. Kaufmann, Julia A. Elvin, Douglas I. Lin, Setsuko K. Chambers, Erin Dominy, Lan-Thanh Vo, Sandra Goble, Lara Maloney, Heidi Giordano, Thomas Harding, Alexander Dobrovic, Clare L. Scott, Kevin Lin, Iain A. McNeish - Nature Communications 2021 cited by 205

  13. Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer

    Authors: Nikki Burdett, Madelynne O. Willis, Kathryn Alsop, Allison L. Hunt, Ahwan Pandey, Phineas T. Hamilton, Tamara Abulez, Xuan Liu, Therese Hoang, Stuart Craig, Sián Fereday, Joy Hendley, Dale W. Garsed, Katy Milne, Shreena Kalaria, Ashley Marshall, Brian L. Hood, Katlin N. Wilson, Kelly A. Conrads, Kathleen I. Pishas, Sumitra Ananda, Clare L. Scott, Yoland Antill, Orla McNally, Linda Mileshkin, Anne Hamilton, George Au‐Yeung, Lisa Devereux, Heather Thorne, Andrea H. Bild, Nicholas W. Bateman, G. Larry Maxwell, Jeffrey T. Chang, Thomas P. Conrads, Brad H. Nelson, David D.L. Bowtell, Elizabeth L. Christie - Nature Genetics 2023 cited by 86

  14. Interferon-ε is a tumour suppressor and restricts ovarian cancer

    Authors: Zoe R. C. Marks, Nicole K. Campbell, Niamh E. Mangan, Cassandra J. Vandenberg, Linden J. Gearing, Antony Y. Matthews, Jodee A. Gould, Michelle D. Tate, Georgie Wray‐McCann, Le Ying, Sarah Rosli, Natasha K. Brockwell, Belinda S. Parker, San Sui Lim, Maree Bilandzic, Elizabeth L. Christie, Andrew N. Stephens, Eveline D. de Geus, Matthew J. Wakefield, Gwo‐Yaw Ho, Orla McNally, Australian Ovarian Cancer Study, David D.L. Bowtell, Penelope M. Webb, Anna DeFazio, Nadia Traficante, Sián Fereday, Leanne Bowes, Joy Hendley, Iain A. McNeish, David D.L. Bowtell, Nicole A. de Weerd, Clare L. Scott, Nollaig M. Bourke, Paul J. Hertzog - Nature 2023 cited by 70

  15. The role of aberrant DNA methylation in cancer initiation and clinical impacts

    Authors: Franziska Geissler, Ksenija Nesic, Olga Kondrashova, Alexander Dobrovic, Elizabeth M. Swisher, Clare L. Scott, Matthew J. Wakefield - Therapeutic Advances in Medical Oncology 2024 cited by 91

  16. Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma

    Authors: Ksenija Nesic, Olga Kondrashova, Rachel M. Hurley, Cordelia D. McGehee, Cassandra J. Vandenberg, Gwo‐Yaw Ho, Elizabeth Lieschke, Genevieve Dall, Nirashaa Bound, Kristy Shield‐Artin, Marc R. Radke, Ashan Musafer, Zi Qing Chai, Mohammad Reza Eftekhariyan Ghamsari, Maria I. Harrell, Damien Kee, Inger Olesen, Orla McNally, Nadia Traficante, Australian Ovarian Cancer Study, Anna DeFazio, David D.L. Bowtell, Elizabeth M. Swisher, S. John Weroha, Kátia Nones, Nicola Waddell, Scott H. Kaufmann, Alexander Dobrovic, Matthew J. Wakefield, Clare L. Scott - Cancer Research 2021 cited by 86

  17. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized

    Authors: Mark F. van Delft, Andrew H. Wei, Kylie D. Mason, Cassandra J. Vandenberg, Lin Chen, Peter E. Czabotar, Simon N. Willis, Clare L. Scott, Catherine L. Day, Suzanne Cory, Jerry M. Adams, Andrew W. Roberts, David C.S. Huang - Cancer Cell 2006 cited by 1,220

  18. CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer

    Authors: Elaine Sanij, Katherine M. Hannan, Jiachen Xuan, Shunfei Yan, Jessica E. Ahern, Anna Trigos, Natalie Brajanovski, Jinbae Son, Keefe T. Chan, Olga Kondrashova, Elizabeth Lieschke, Matthew J. Wakefield, Daniel Frank, Sarah Ellis, Carleen Cullinane, Jian Kang, Gretchen Poortinga, Purba Nag, Andrew J. Deans, Kum Kum Khanna, Linda Mileshkin, Grant A. McArthur, John Soong, Els M.J.J. Berns, Ross D. Hannan, Clare L. Scott, Karen E. Sheppard, Richard B. Pearson - Nature Communications 2020 cited by 219

  19. p53 Efficiently Suppresses Tumor Development in the Complete Absence of Its Cell-Cycle Inhibitory and Proapoptotic Effectors p21, Puma, and Noxa

    Authors: Liz J. Valente, Daniel H.D. Gray, Ewa M. Michalak, Josefina Piñón Hofbauer, Alex Egle, Clare L. Scott, Ana Janic, Andreas Strasser - Cell Reports 2013 cited by 295

  20. DNA Damage-Induced Primordial Follicle Oocyte Apoptosis and Loss of Fertility Require TAp63-Mediated Induction of Puma and Noxa

    Authors: J. B. Kerr, Karla J. Hutt, Ewa M. Michalak, Michele Cook, Cassandra J. Vandenberg, Seng H. Liew, Philippe Bouillet, Alea A. Mills, Clare L. Scott, Jock K. Findlay, Andreas Strasser - Molecular Cell 2012 cited by 267

  21. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial

    Authors: Jonathan A. Ledermann, Philipp Harter, Charlie Gourley, Michael Friedländer, Ignace Vergote, Gordon Rustin, Clare L. Scott, Werner Meier, Ronnie Shapira‐Frommer, Tamar Safra, Daniela Matei, Anitra Fielding, Stuart Spencer, Philip Rowe, Elizabeth Lowe, Darren Hodgson, Mika A. Sovak, Ursula A. Matulonis - The Lancet Oncology 2016 cited by 452

  22. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy

    Authors: Michael Friedländer, Ursula A. Matulonis, Charlie Gourley, Andreas du Bois, Ignace Vergote, Gordon Rustin, Clare L. Scott, Werner Meier, Ronnie Shapira‐Frommer, Tamar Safra, Daniela Matei, Vadim Shirinkin, Frédèric Selle, Anitra Fielding, Elizabeth Lowe, Emma McMurtry, Stuart Spencer, Philip Rowe, Helen Mann, David Parry, Jonathan A. Ledermann - British Journal of Cancer 2018 cited by 183

  23. Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers

    Authors: Oliver Klein, Damien Kee, Ben Markman, Michael Michael, Craig Underhill, Matteo S. Carlino, Louise Jackett, Caroline Lum, Clare L. Scott, Adnan Nagrial, Andreas Behren, Jane Y. So, Jodie Palmer, Jonathan Cebon - Clinical Cancer Research 2020 cited by 172

  24. Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization

    Authors: Stéphanie Lheureux, Zhongwu Lai, Brian Dougherty, Sarah Runswick, Darren Hodgson, Kirsten M. Timms, Jerry S. Lanchbury, Stan Kaye, Charlie Gourley, David D.L. Bowtell, Elise C. Kohn, Clare L. Scott, Ursula A. Matulonis, Tony Panzarella, Katherine Karakasis, Julia V. Burnier, C. Blake Gilks, Mark J. O’Connor, Jane Robertson, Jonathan A. Ledermann, J. Carl Barrett, Tony W. Ho, Amit M. Oza - Clinical Cancer Research 2017 cited by 154